| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 20,611 | 28,415 | ||
| Marketable securities | 4,992 | 9,932 | ||
| Prepaid expenses and other current assets | 3,221 | 3,742 | ||
| Total current assets | 28,824 | 42,089 | ||
| Long-term equity investments | 20,908 | 20,908 | ||
| Restricted cash | 1,931 | 1,931 | ||
| Right-of-use asset, net | 11,916 | 12,215 | ||
| Property and equipment, net | 269 | 285 | ||
| Other noncurrent assets | 0 | 0 | ||
| Total assets | 63,848 | 77,428 | ||
| Accounts payable | 1,710 | 3,950 | ||
| Accrued expenses | 2,959 | 2,872 | ||
| Current portion, lease liability | 1,409 | 1,384 | ||
| Deferred revenue | 718 | 718 | ||
| Total current liabilities | 6,796 | 8,924 | ||
| Lease liability | 12,354 | 12,715 | ||
| Total liabilities | 19,150 | 21,639 | ||
| Common stock, 0.001 par value 125,000,000 shares authorized 71,151,981 and 71,009,866 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 71 | 71 | ||
| Additional paid-in-capital | 376,129 | 375,005 | ||
| Accumulated other comprehensive loss | -126 | -69 | ||
| Accumulated deficit | -331,376 | -319,218 | ||
| Total stockholders equity | 44,698 | 55,789 | ||
| Total liabilities and stockholders equity | 63,848 | 77,428 | ||
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)